Amalgamated Bank Purchases Shares of 2,827 CRISPR Therapeutics AG $CRSP

Amalgamated Bank purchased a new position in CRISPR Therapeutics AG (NASDAQ:CRSP) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 2,827 shares of the company’s stock, valued at approximately $138,000.

Other large investors also recently modified their holdings of the company. ARK Investment Management LLC grew its stake in shares of CRISPR Therapeutics by 13.3% during the first quarter. ARK Investment Management LLC now owns 10,165,400 shares of the company’s stock worth $345,929,000 after purchasing an additional 1,192,336 shares in the last quarter. B & T Capital Management DBA Alpha Capital Management acquired a new stake in CRISPR Therapeutics in the first quarter valued at $416,000. IVC Wealth Advisors LLC acquired a new stake in CRISPR Therapeutics in the second quarter valued at $225,000. Koss Olinger Consulting LLC lifted its holdings in CRISPR Therapeutics by 29.8% during the 2nd quarter. Koss Olinger Consulting LLC now owns 42,197 shares of the company’s stock worth $2,052,000 after buying an additional 9,685 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of CRISPR Therapeutics by 1.9% during the 1st quarter. Vanguard Group Inc. now owns 1,769,709 shares of the company’s stock worth $60,223,000 after acquiring an additional 33,711 shares in the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Stock Down 2.6%

Shares of NASDAQ:CRSP opened at $55.12 on Friday. CRISPR Therapeutics AG has a fifty-two week low of $30.04 and a fifty-two week high of $78.48. The firm’s 50-day simple moving average is $62.93 and its 200-day simple moving average is $53.12. The company has a market cap of $5.01 billion, a price-to-earnings ratio of -10.15 and a beta of 1.89.

Insider Activity at CRISPR Therapeutics

In other news, General Counsel James R. Kasinger sold 1,076 shares of the stock in a transaction that occurred on Tuesday, October 14th. The stock was sold at an average price of $66.60, for a total transaction of $71,661.60. Following the completion of the transaction, the general counsel directly owned 83,402 shares of the company’s stock, valued at approximately $5,554,573.20. This represents a 1.27% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Samarth Kulkarni sold 50,895 shares of CRISPR Therapeutics stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $67.91, for a total value of $3,456,279.45. Following the completion of the sale, the chief executive officer owned 254,201 shares in the company, valued at approximately $17,262,789.91. This trade represents a 16.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 56,213 shares of company stock worth $3,810,458 in the last quarter. 4.30% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research firms have weighed in on CRSP. Weiss Ratings reissued a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Wednesday, October 8th. Barclays lifted their price target on shares of CRISPR Therapeutics from $42.00 to $56.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Chardan Capital restated a “buy” rating and issued a $82.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, August 5th. Royal Bank Of Canada raised their price objective on CRISPR Therapeutics from $38.00 to $42.00 and gave the stock a “sector perform” rating in a report on Tuesday, August 5th. Finally, Bank of America boosted their target price on CRISPR Therapeutics from $78.00 to $93.00 and gave the company a “buy” rating in a report on Friday, October 17th. Eleven analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $69.06.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.